Sandoz
Sandoz, a division of Novartis, is a global leader in the pharmaceutical industry, headquartered in Switzerland (CH). Founded in 1886, Sandoz has established itself as a pioneer in generic and biosimilar medicines, focusing on high-quality, affordable healthcare solutions. With a strong presence in Europe, North America, and emerging markets, the company is dedicated to improving patient access to essential medications. Sandoz's core offerings include a diverse range of generic pharmaceuticals, biosimilars, and over-the-counter products, distinguished by their rigorous quality standards and innovative approaches. The company has achieved significant milestones, including the launch of several groundbreaking biosimilars, solidifying its position as a trusted partner in the healthcare sector. With a commitment to sustainability and patient-centric solutions, Sandoz continues to shape the future of medicine.
DitchCarbon Score
How does Sandoz's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sandoz's score of 56 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Sandoz's reported carbon emissions
In 2023, Sandoz, headquartered in Switzerland (CH), reported total carbon emissions of approximately 2,278,340,000 kg CO2e. This figure includes 86,200,000 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources, and 122,300,000 kg CO2e from Scope 2 emissions, representing indirect emissions from the generation of purchased electricity, steam, heating, and cooling. Notably, Sandoz also disclosed Scope 3 emissions, which totalled about 2,051,700,000 kg CO2e, covering a wide range of indirect emissions across its value chain. In comparison, the previous year, 2022, Sandoz's emissions were approximately 159,420,000 kg CO2e from Scope 1 and Scope 2 combined, indicating a significant increase in total emissions in 2023. The company has committed to near-term climate targets but has not set a net-zero target as of now. Sandoz's ongoing efforts reflect a commitment to addressing climate change within the pharmaceuticals, biotechnology, and life sciences sector, although specific reduction targets have not been publicly detailed.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 75,620,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 158,430,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sandoz is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
